Sysmex America to distribute CellaVision DC-1 for low-volume haematology labs

CellaVision DC-1 automates and simplifies the process of performing blood cell differentials in low volume labs

Sysmex America, a leading diagnostic company offering haematology, urinalysis, informatics systems and flow cytometry testing solutions for optimal clinical laboratory performance, will add the CellaVision DC-1 to its portfolio of CellaVision products for low-volume haematology labs. The product received the Food and Drug Administration’s 510(k) clearance on October 16, 2020. Now available in the US and Canada, the CellaVision DC-1 automates and simplifies the process of performing blood cell differentials in low volume labs.

“The solution for both standalone and networked installation, the CellaVision DC-1 closes the technology gap between larger and smaller labs,” said Andy Hay, COO, Sysmex America. “The CellaVision DC-1 provides labs high quality digital imaging for improved efficiency, quality, connectivity and staff proficiency.”

The CellaVision DC-1 eliminates the majority of manual steps traditionally done by lab technicians performing blood cell differentials for maximum speed and productivity. It’s more standardised testing process helps reduce the negative impact of subjective interpretations and assessments.

“Enabling smaller labs across the globe to benefit from the same set of well-documented operational and clinical implementation benefits that we have provided larger labs has been a high priority for us,” said Zlatko Rihter, President and CEO, CellaVision. “We are pleased to expand our long-standing partnership with Sysmex America as they bring the CellaVision DC-1 to the US market.”